(CBA × C57B1)F1 mice were primed to the hapten NNP on either of the non-cross-reacting carriers fowl γ-globulin (Fγ G) or ovalbumin (OV) and 4 weeks later were given 50 × 106 CBA or (CBA × C57B1)F1 spleen cells. When challenged on the same day with NNP.Fγ G, the two groups of mice undergoing a graft-versus-host reaction (GVHR) showed higher numbers of antibody-producing cells to both NNP and Fγ G determinants. The antibody-forming cells were of host origin, and the effect could be induced by T lymphocytes, not by B. When mice were challenged with NNP.Fγ G at various intervals after the induction of GVHR, it was found that by 8 days the increased response was seen only in mice primed to hapten on the heterologous carrier (NNP.OV). Increased antibody formation was not seen in primed CBA mice injected with (CBA × C57B1)F1 spleen cells, or in normal (CBA × C57B1)F1 mice injected with primed CBA cells. When mice undergoing GVHR were lethally irradiated, they did not increase the response of primed (CBA × C57B1)F1 cells transferred to them. The relevance of these findings to the mechanism of interaction between T and B cells is discussed.

This content is only available via PDF.
© 1973 S. Karger AG, Basel
1973
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.